Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.20M | 4.96M | 5.91M | 5.43M | 4.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.17M | 24.85M | 27.67M | 24.35M | 22.81M |
| Operating Income | -27.17M | -24.85M | -27.67M | -24.35M | -22.81M |
| Income Before Tax | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M |
| EBIT | -27.17M | -24.85M | -27.67M | -24.35M | -22.81M |
| EBITDA | -26.99M | -24.66M | -27.48M | -24.16M | -22.60M |
| EPS Basic | -0.42 | -0.39 | -0.44 | -0.38 | -0.35 |
| Normalized Basic EPS | -0.26 | -0.24 | -0.27 | -0.24 | -0.22 |
| EPS Diluted | -0.42 | -0.39 | -0.44 | -0.38 | -0.35 |
| Normalized Diluted EPS | -0.26 | -0.24 | -0.27 | -0.24 | -0.22 |
| Average Basic Shares Outstanding | 64.24M | 63.28M | 61.94M | 61.77M | 61.87M |
| Average Diluted Shares Outstanding | 64.24M | 63.28M | 61.94M | 61.77M | 61.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |